NASDAQ:EARS - Auris Medical Stock Price, Forecast & News

Auris Medical trades on the NASDAQ under the ticker symbol "EARS."

Auris Medical's stock reverse split on Wednesday, May 1st 2019. The 1-20 reverse split was announced on Tuesday, April 30th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 30th 2019. An investor that had 100 shares of Auris Medical stock prior to the reverse split would have 5 shares after the split.

Auris Medical Holding Ltd (NASDAQ:EARS) announced its quarterly earnings results on Thursday, May, 11th. The biotechnology company reported ($4.40) earnings per share for the quarter, missing the Zacks' consensus estimate of ($2.80) by $1.60. View Auris Medical's Earnings History.

Auris Medical is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Auris Medical.

Media coverage about EARS stock has been trending somewhat positive on Monday, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Auris Medical earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Auris Medical.

Auris Medical saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 46,800 shares, an increase of 97.5% from the December 15th total of 23,700 shares. Based on an average daily volume of 178,900 shares, the days-to-cover ratio is presently 0.3 days. Currently, 3.0% of the shares of the company are sold short. View Auris Medical's Current Options Chain.

Some companies that are related to Auris Medical include Amarillo Biosciences (AMAR), Kaya (KAYS), Tonix Pharmaceuticals (TNXP), Acura Pharmaceuticals (ACUR), Rexahn Pharmaceuticals (REXN), Pivot Pharmaceuticals (PVOTF), Novus Therapeutics (NVUS), Tetraphase Pharmaceuticals (TTPH), iCo Therapeutics (ICOTF), Capricor Therapeutics (CAPR), Integrated BioPharma (INBP), DelMar Pharmaceuticals (DMPI), Reliv International (RELV), Genprex (GNPX) and International Stem Cell (ISCO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Auris Medical investors own include Helios and Matheson Analytics (HMNY), TransEnterix (TRXC), Anavex Life Sciences (AVXL), Rigel Pharmaceuticals (RIGL), Flexion Therapeutics (FLXN), RXi Pharmaceuticals (RXII), Sophiris Bio (SPHS), Iconix Brand Group (ICON), Magnegas Applied Tchnlgy Sltns (MNGA) and Progenics Pharmaceuticals (PGNX).

Auris Medical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Wedbush Securities Inc. (1.18%).

EARS stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc..

Shares of EARS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EARS stock can currently be purchased for approximately $1.55.

Auris Medical has a market capitalization of $2.89 million. The biotechnology company earns $-11,750,000.00 in net income (profit) each year or ($14.80) on an earnings per share basis. Auris Medical employs 9 workers across the globe.View Additional Information About Auris Medical.

The official website for Auris Medical is http://www.aurismedical.com/.

Auris Medical's mailing address is BAHNHOFSTRASSE 21, ZUG V8, 6300. The biotechnology company can be reached via phone at 41-41-729-7194 or via email at [email protected]